New Jersey S4222 aims to improve access to lower-cost generic and biosimilar drugs.

New Jersey S4222 seeks to enhance access to lower-cost generic and biosimilar drugs by requiring managed care organizations and vendors to make these drugs available on their formularies with more favorable cost sharing. The bill mandates that if a biosimilar is available, it should be prescribed to covered persons or enrollees who have not previously been treated with the prescribed brand drug.

New Jersey S4222 aims to improve access to lower-cost generic and biosimilar drugs.

New Jersey S4222 seeks to enhance access to lower-cost generic and biosimilar drugs by requiring managed care organizations and vendors to make these drugs available on their formularies with more favorable cost sharing. The bill mandates that if a biosimilar is available, it should be prescribed to covered persons or enrollees who have not previously been treated with the prescribed brand drug.